绥美凯主治什么？

It is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40kg) infected with human immunodeficiency virus (HIV). Suimeikai is composed of three ingredients: DTG (DTG) + Abacavir (ABC) + Lamivudine (3TC). It is a compound treatment agent of integrase inhibitors and nucleoside drugs. Since the advent of the first anti-HIV drug zidovudine (AZT) in 1987, it has brought life hope to AIDS patients. Subsequently, more and more drugs have continued to appear, with more and more types of drugs, better and better therapeutic effects, and fewer and fewer side effects. At present, the world has basically entered the era of integrase inhibitor drugs, and continues to introduce new ones in the optimization of multi-drug combination regimens. Today let’s find out what Sui Meikai specializes in?

On January 22, 2018, Suimeike was launched in China and is suitable for the treatment of adults and adolescents over 12 years old (with a weight of at least 40 kg) infected with human immunodeficiency virus (HIV). HIV-infected patients, regardless of race, should be screened for the HLA-B5701 allele before starting treatment with abacavir-containing products. If the patient is known to carry the HLA-B5701 allele, he should not take products containing abacavir.

Suimeikai is a treatment plan based on DTG, an integrase inhibitor, as the core drug, coupled with two backbone drugs, abacavir and lamivudine, and made into a single-tablet treatment for promotion, which has made great progress in the HAART treatment of the core drugs. 

Trimax is suitable for adults and adolescents over 12 years old and weighing no less than 40kg. Since the ingredients in Trimax may cause hypersensitivity reactions, patients should be screened for HLA-B*5701 alleles before starting treatment with abacavir-containing products, regardless of race. 

The recommended dosage of SuimeiKai is one tablet, once daily. Adults or adolescents whose weight is less than 40kg should not be given Trimax, because Trimax is a fixed-dose tablet and the dose cannot be reduced. Reducing the dose without authorization may result in the inefficiency of the drug. Clinical data on Trimax are limited, and the most commonly reported adverse reactions that are possibly or probably related to dolutegravir and abacalongvir/lamivudine are nausea (12%), insomnia (7%), dizziness (6%), and headache (6%).

The above is the content of the indications, I hope it can help you!